Drug of Choice for Supraventricular Tachycardia (SVT)

Introduction

Supraventricular tachycardia (SVT) is a rapid heart rhythm originating above the ventricles, typically involving the atria or the atrioventricular (AV) node. It often presents with symptoms such as palpitations, dizziness, or shortness of breath. The treatment approach depends on the clinical presentation and whether the patient is hemodynamically stable or unstable.

Treatment Approaches

1. Immediate Management (Acute Episodes)

  • Vagal Maneuvers: First-line treatment for stable patients. Techniques such as the Valsalva maneuver or carotid sinus massage may help terminate the arrhythmia.
  • Adenosine (First-line pharmacologic choice):
    • Initial dose: 6 mg IV rapid push, followed by a flush.
    • If ineffective, a second dose of 12 mg IV may be given.
    • Temporarily blocks the AV node, interrupting the re-entrant circuit.
  • If adenosine is contraindicated or ineffective:
    • Calcium Channel Blockers (e.g., verapamil or diltiazem) or
    • Beta-Blockers (e.g., metoprolol, esmolol) can be used.

2. Management of Unstable Patients

  • If the patient has hypotension, chest pain, or signs of shock, immediate synchronized cardioversion is required.

3. Chronic Prevention (Recurrent SVT)

  • Beta-blockers or Calcium Channel Blockers for long-term management.
  • Catheter Ablation: Preferred in patients with frequent recurrences or those who do not tolerate medications well.

Conclusion

Adenosine remains the drug of choice for acute management of SVT due to its rapid onset and high efficacy. However, beta-blockers or calcium channel blockers may be used as second-line agents, particularly for chronic therapy.

References

Relevant clinical guidelines:

Source recommendations

1. American Heart Association (AHA) Guidelines on Supraventricular Arrhythmias

  1. https://www.ahajournals.org/doi/10.1161/cir.0000000000000311
  2. https://www.heart.org/en/health-topics/arrhythmia/about-arrhythmia/tachycardia--fast-heart-rate
  3. https://pubmed.ncbi.nlm.nih.gov/14557344/
  4. https://www.ahajournals.org/doi/10.1161/01.cir.0000091380.04100.84
  5. https://professional.heart.org/en/science-news/-/media/028ddd505f514ea2b3a4e74bb72e3557.ashx

2. European Society of Cardiology (ESC) Guidelines for the Management of Supraventricular Tachycardia

  1. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Supraventricular-Tachycardia
  2. https://academic.oup.com/eurheartj/article/41/5/655/5556821
  3. https://pubmed.ncbi.nlm.nih.gov/31504425/
  4. https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2019/09/10/12/36/2019-ESC-Guidelines-for-Supraventricular-Tachycardia
  5. https://pubmed.ncbi.nlm.nih.gov/14563598/

Our advantages:

patient2376100
Best practices from USA, EU and Japan
Our answers to your questions are based on the clinical recommendations of countries with the most developed healthcare systems in the field of cardiology in the USA, the EU and Japan.
prescription18648039
Always up-to-date information
On a daily basis, we monitor for you all new scientific research publications in leading scientific journals on medical issues of interest to you.
We monitor all innovations and changes in the field of cardiac disease treatment on a daily basis.
fvfflf7q
Get second opinion
Here you can learn everything that even your doctor may not know about cardiology (if he does not speak English and he does not read 117 leading medical journals on cardiology every month).
1xr4duup
The most comprehensive and up-to-date collection of free cardiology materials
Our website contains the most comprehensive and up-to-date collection of free cardiology materials in your country.
Every 3-5 years, half of the scientific approaches to treatment in the field of cardiology are reviewed as a result of specialized scientific discoveries. With us, you don't have to wait these years to learn about the best ways to treat you and your loved ones.
arrow
Please register in order to receive information regarding possible complications and new approaches to treatment of cardiovascular diseases via email in our Newsletters.
arrow